A case series from the National Institutes of Health1 and two single case-reports2,3 indicate that some cases of progressive multifocal leukoencephalomyelopathy (PML) can benefit from treatment with pembrolizumab or nivolumab, which are anti-programmed death protein 1 (PD-1) checkpoint-blocking antibodies.